Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that functions as a viscoelastic substance. It is available in various formulations for different indications.
## Primary Indications
* **Ophthalmology:** Intraocular lens insertion, anterior and posterior segment surgery (e.g., cataract surgery, retinal detachment repair), corneal transplantation.
* **Osteoarthritis:** Intra-articular injection for symptomatic relief of knee osteoarthritis.
* **Dermatology/Wound Healing:** Topical formulations for skin hydration and wound healing.
* **Cosmetic:** Dermal fillers for aesthetic enhancement.
## Adult Dosing
* **Ophthalmology:** Typically 0.5 mL to 2 mL per procedure, depending on the specific product and surgical technique. The amount used is guided by surgical needs.
* **Osteoarthritis (Knee):** Commonly administered as a single intra-articular injection of 2 mL (e.g., 20 mg/2 mL) or a series of injections (e.g., 3-5 weekly injections of 2 mL). Specific regimens vary by product and may be guided by local protocol.
* **Topical:** Applied as directed by the product manufacturer, typically once or twice daily.
* **Dermal Fillers:** Administered by a qualified healthcare professional based on aesthetic goals.
## Pediatric Dosing
No established pediatric dosing for intra-articular or ophthalmic indications. Topical formulations may be used off-label; consult specific product information and clinical judgment.
## Dose Adjustments
No dose adjustments are typically required for renal or hepatic impairment. Dosing is procedure- or symptom-dependent.
## Contraindications
* Known hypersensitivity to hyaluronic acid or any component of the formulation.
* Active joint infection or severe inflammation for intra-articular injections.
* Skin infection at the intended injection site for dermal fillers.
## Adverse Effects
* **Ophthalmology:** Transient increase in intraocular pressure, corneal edema, anterior chamber inflammation, post-operative cystoid macular edema.
* **Osteoarthritis:** Localized pain, swelling, stiffness, effusion at the injection site.
* **Topical:** Mild skin irritation.
* **Dermal Fillers:** Bruising, swelling, redness, pain, nodule formation, infection, vascular occlusion (rare but serious).
## Key Drug Interactions
* **Ophthalmology:** Concurrent use of other intraocular medications should be managed carefully to avoid additive effects or interactions.
* **Osteoarthritis:** No significant drug interactions are expected with systemic medications.
## Monitoring
* **Ophthalmology:** Intraocular pressure, signs of inflammation, visual acuity post-procedure.
* **Osteoarthritis:** Pain and functional status of the knee. Monitor for signs of infection at the injection site.
* **Dermal Fillers:** Monitor for adverse reactions, particularly signs of infection or vascular compromise.
## Clinical Pearls
* Hyaluronic acid viscoelastic solutions are designed to protect ocular tissues during surgery.
* Intra-articular HA for osteoarthritis may provide symptomatic relief for up to 6 months.
* Topical HA is a humectant that can improve skin hydration.
* Ensure aseptic technique for all injectable formulations.
* For dermal fillers, understanding the rheological properties of different HA products is crucial for achieving desired aesthetic outcomes and minimizing complications.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant literature for the specific product being used. Dosing and recommendations may vary based on local protocols and individual patient factors.
